Rathbones Group PLC Has $47.19 Million Holdings in Zoetis Inc. $ZTS

Rathbones Group PLC lessened its stake in Zoetis Inc. (NYSE:ZTS) by 29.5% in the 4th quarter, HoldingsChannel reports. The institutional investor owned 375,031 shares of the company’s stock after selling 157,033 shares during the quarter. Rathbones Group PLC’s holdings in Zoetis were worth $47,186,000 as of its most recent SEC filing.

Several other large investors also recently made changes to their positions in ZTS. Vanguard Group Inc. boosted its holdings in shares of Zoetis by 12.9% in the 4th quarter. Vanguard Group Inc. now owns 47,780,974 shares of the company’s stock valued at $6,011,802,000 after buying an additional 5,474,210 shares during the last quarter. Diamond Hill Capital Management Inc. acquired a new stake in Zoetis during the 3rd quarter valued at $394,010,000. Nordea Investment Management AB lifted its holdings in Zoetis by 79.2% during the 4th quarter. Nordea Investment Management AB now owns 4,932,787 shares of the company’s stock valued at $622,222,000 after purchasing an additional 2,179,578 shares during the last quarter. Montrusco Bolton Investments Inc. lifted its holdings in Zoetis by 256.7% during the 4th quarter. Montrusco Bolton Investments Inc. now owns 2,168,078 shares of the company’s stock valued at $266,888,000 after purchasing an additional 1,560,314 shares during the last quarter. Finally, Arrowstreet Capital Limited Partnership lifted its holdings in Zoetis by 83.4% during the 3rd quarter. Arrowstreet Capital Limited Partnership now owns 2,697,827 shares of the company’s stock valued at $394,746,000 after purchasing an additional 1,227,085 shares during the last quarter. Institutional investors and hedge funds own 92.80% of the company’s stock.

Analyst Upgrades and Downgrades

ZTS has been the subject of several research reports. Leerink Partners reaffirmed a “market perform” rating on shares of Zoetis in a report on Tuesday, March 10th. UBS Group cut their price target on Zoetis from $130.00 to $99.00 and set a “neutral” rating for the company in a report on Friday, May 8th. Weiss Ratings downgraded Zoetis from a “hold (c-)” rating to a “sell (d+)” rating in a report on Friday, March 27th. William Blair reaffirmed an “outperform” rating on shares of Zoetis in a report on Monday, March 2nd. Finally, Piper Sandler reaffirmed a “neutral” rating and set a $135.00 price target (down from $190.00) on shares of Zoetis in a report on Thursday, January 22nd. Seven research analysts have rated the stock with a Buy rating, seven have issued a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, Zoetis has a consensus rating of “Hold” and an average price target of $134.75.

Insiders Place Their Bets

In other Zoetis news, Director Paul Bisaro bought 2,000 shares of the firm’s stock in a transaction on Wednesday, May 13th. The shares were purchased at an average price of $75.88 per share, for a total transaction of $151,760.00. Following the transaction, the director directly owned 27,862 shares in the company, valued at approximately $2,114,168.56. This trade represents a 7.73% increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, Director Frank A. Damelio purchased 6,650 shares of the company’s stock in a transaction dated Wednesday, May 13th. The stock was acquired at an average price of $75.39 per share, with a total value of $501,343.50. Following the completion of the transaction, the director owned 21,458 shares of the company’s stock, valued at $1,617,718.62. This represents a 44.91% increase in their position. The disclosure for this purchase is available in the SEC filing. Insiders have acquired a total of 11,650 shares of company stock worth $886,384 in the last quarter. Corporate insiders own 0.22% of the company’s stock.

Zoetis Stock Up 0.9%

ZTS stock opened at $79.64 on Thursday. The company has a debt-to-equity ratio of 2.80, a current ratio of 3.15 and a quick ratio of 1.91. The stock has a market capitalization of $33.39 billion, a price-to-earnings ratio of 13.21, a PEG ratio of 1.29 and a beta of 0.87. The business’s fifty day moving average price is $109.69 and its two-hundred day moving average price is $119.37. Zoetis Inc. has a fifty-two week low of $72.38 and a fifty-two week high of $172.23.

Zoetis (NYSE:ZTS) last posted its quarterly earnings data on Thursday, May 7th. The company reported $1.53 earnings per share for the quarter, missing the consensus estimate of $1.60 by ($0.07). The firm had revenue of $2.26 billion for the quarter, compared to the consensus estimate of $2.30 billion. Zoetis had a return on equity of 66.85% and a net margin of 27.80%.The firm’s quarterly revenue was up 2.9% on a year-over-year basis. During the same quarter in the previous year, the business earned $1.48 EPS. Zoetis has set its FY 2026 guidance at 6.850-7.000 EPS. On average, equities analysts anticipate that Zoetis Inc. will post 6.88 earnings per share for the current year.

About Zoetis

Zoetis Inc (NYSE: ZTS) is a global animal health company that develops, manufactures and markets a broad portfolio of products and services for companion animals and livestock. The company’s offerings include pharmaceuticals, vaccines and biologics, parasiticides and anti-infectives, as well as diagnostic instruments, consumables and laboratory testing services. Zoetis serves the veterinary community, livestock producers and other animal-health customers with products designed to prevent, detect and treat disease and to support animal productivity and welfare.

Zoetis traces its roots to the animal health business of Pfizer and became an independent, publicly traded company following a 2013 separation and initial public offering.